Diuretic Drugs Market

Diuretic Drugs Market (Drug Class: Carbonic Anhydrase Inhibitors, Loop Diuretics, Miscellaneous Diuretics, Potassium-sparing Diuretics, and Thiazide Diuretics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Diuretic Drugs Market Outlook 2031

  • The global industry was valued at US$ 98.8 Mn in 2022
  • It is projected to grow at a CAGR of 5.5% from 2023 to 2031 and reach more than US$ 157.2 Mn by the end of 2031

Analysts’ Viewpoint

Increase in prevalence of chronic diseases, including heart diseases, stroke, diabetes, hypertension, and cancer, is projected to augment diuretic drugs market value in the near future. Rise in demand for diuretic drugs among athletes is also fueling market progress. Growth in awareness about benefits of diuretic drugs among those suffering from various chronic disorders is expected to boost the global diuretic drugs market scope during the forecast period.

Rise in aging population, increase in adoption of unhealthy lifestyle, and surge in rate of obesity are also driving market dynamics. Growth in adoption of diuretic drugs in emerging economies is creating lucrative opportunities for market players. Companies in the global market are introducing new medications to treat several chronic diseases.

Diuretic Drugs Market

Market Introduction

Diuretics, sometimes known as water pills or fluid pills, are medications that increase urine production. The body uses urination to eliminate extra salt and water. This helps reduce blood pressure in addition to relieving symptoms such as ankle swelling.

Carbonic anhydrase inhibitors, loop diuretics, potassium-sparing diuretics, and thiazide diuretics are some of the common types of diuretic drugs. Thiazides are the most common diuretics for hypertension. Heart failure is often treated with loop diuretics. These medications include bumetanide, torsemide (demadex), and furosemide (lasix).

Potassium is an essential nutrient that lowers the amount of fluid in the body. Potassium-sparing diuretics may be administered to people who are at the risk of low potassium levels, including those who take other drugs that deplete potassium.

Increase in Demand for Diuretic Drugs Among Athletes

Some athletes use diuretics to lose weight quickly, especially in sports that emphasize weight classes or body appearances, such as wrestling, boxing, and bodybuilding. Diuretics are substances that increase the amount of urine produced by the body, leading to a rapid loss of water weight. Athletes may use diuretics to achieve a certain weight class or enhance their muscle definition by reducing water retention and bloating.

However, the usage of diuretics for weight loss is considered a deceitful practice in sports. It is banned by most athletic organizations. Diuretics are classified as masking agents; they can be used to hide the presence of other banned substances in the body.

Rise in Prevalence of Chronic Diseases to Fuel Global Diuretic Drugs Market Growth

Diuretics are commonly used in the treatment of chronic diseases such as heart failure, kidney disease, and liver cirrhosis. The usage of diuretics in chronic diseases is aimed at managing symptoms and complications associated with these conditions, such as fluid overload, edema, and high blood pressure.

In patients with heart failure, diuretics are often prescribed to reduce fluid buildup in the lungs and other tissues, which can cause shortness of breath, coughing, and fatigue. Diuretics can help reduce the workload on the heart and improve cardiac function, thus leading to better overall health outcomes.

In patients with kidney diseases, diuretics can help reduce fluid overload and manage edema, a common complication of chronic kidney disease. However, the usage of diuretics in kidney disease patients requires close monitoring of the kidney function, electrolyte levels, and blood pressure in order to avoid further damage to the kidneys and other complications.

In patients with cirrhosis of the liver, diuretics can help reduce ascites, a condition where fluid builds up in the abdomen, thus causing discomfort and increased risk of infection.

Diuretics can be effective in managing symptoms and complications of chronic diseases. However, they are not without risks. Common side-effects of diuretics include dehydration, electrolyte imbalances, and low blood pressure, which can be particularly dangerous in patients with chronic diseases.

Growth in Adoption of Thiazide Diuretics

In terms of drug class, the global market has been classified into carbonic anhydrase inhibitors, loop diuretics, miscellaneous diuretics, potassium-sparing diuretics, and thiazide diuretics. The thiazide diuretics segment accounted for major share in 2022.

Thiazide diuretics are less effective at causing diuresis and natriuresis than loop diuretics drugs, as the sodium chloride transporter in the distal tubule typically reabsorbs just around 5.0% of filtered salt. Nevertheless, they are potent enough to address a variety of therapeutic requirements for a diuretic.

Oral Route of Administration of Diuretic Drugs Gaining Traction

Based on route of administration, the global industry has been bifurcated into oral and parenteral. The oral segment accounted for major share in 2022. The segment is estimated to maintain its share throughout the forecast period, as per the latest diuretic drugs market forecast analysis.

According to the latest diuretic drugs market trends, oral administration of diuretic drugs is a commonly used method. It is more convenient than parenteral administration. It is the most prescribed route of drug administration, as it is easy to administer and provides a predictable absorption of the medication.

Surge in Usage of Diuretics in Treatment of Hypertension

Based on indication, the global market has been divided into hypertension, edema, heart failure, kidney stone, and others. According to the latest diuretic drugs market analysis, the hypertension segment accounted for major share of the global market in 2022. The segment is likely to dominate the global landscape in the next few years.

Diuretics are one of the first-line treatments for hypertension, and are commonly prescribed in combination with other antihypertensive medications.

Rise in Availability of Diuretic Drugs in Retail Pharmacies

In terms of distribution channel, the global market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for the largest share in 2022. It is expected to lead the market in the near future. Increase in availability of prescribed oral drugs in retail pharmacies is a key factor augmenting the segment.

Regional Analysis

North America constituted major diuretic drugs market share in 2022. The region is anticipated to maintain its dominance throughout the forecast period. The diuretic drugs market size is projected to increase in North America during the forecast period, owing to the rise in prevalence of chronic diseases in the region.

According to the Centers for Disease Control and Prevention, every six in 10 adults are suffering from chronic diseases in North America. Chronic diseases such as diabetes, cancer, and heart diseases are considered to be the major causes of mortality and disability in the U.S. Increase in healthcare expenditure is also fueling market statistics in the region.

The market in Asia Pacific is likely to grow at a rapid pace from 2023 to 2031. According to the World Health Organization (WHO), 41 million people die from noncommunicable diseases (NCDs) every year, accounting for 74.0% of all deaths worldwide. Rise in incidence of NCDs is fueling the demand for diuretic drugs in the region.

Analysis of Key Players in Global Diuretic Drugs Business

As per the latest diuretic drugs market research report, the global industry is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players.

Prominent players in the global market are AstraZeneca, Aurobindo Pharma, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GSK plc, Hikma Pharmaceuticals PLC, Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, and Teva Pharmaceutical Industries Ltd.

Key Developments in Global Diuretic Drugs Industry  

  • On February 17, 2023, Travere Therapeutics, a leading biopharmaceutical company, announced the FDA approval for "FILSPARI" (sparsentan) to treat people with primary IgAN. This drug is beneficial for patients who are at the risk of fast illness progression and who have a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g.
  • In January 2023, Glenmark Pharmaceuticals Limited released a generic version of the diuretic bumetanide injection. These injections are the generic form of Bumex injection, 0.25 mg/mL, made by Validus Pharmaceuticals LLC.
  • In October 2022, scPharmaceuticals, a leading pharmaceutical company, announced the FDA approval for FUROSCIX (furosemide injection). It is a self-administered injection used for the treatment of congestion in chronic heart failure at home.

Key players have been profiled in the diuretic drugs market report based on parameters such as company overview, recent developments, product portfolio, financial overview, business segments, and business strategies.

Market Snapshot

Attribute

Detail

Market Size Value in 2022

US$ 98.8 Mn

Market Forecast Value in 2031

US$ 157.2 Mn

Growth Rate

(CAGR)

 5.5%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Carbonic Anhydrase Inhibitors
    • Loop Diuretics
    • Miscellaneous Diuretics
    • Potassium-sparing Diuretics
    • Thiazide Diuretics
  • Route of Administration
    • Oral
    • Parenteral
  • Indication
    • Hypertension
    • Edema
    • Heart Failure
    • Kidney Stone
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AstraZeneca
  • Aurobindo Pharma
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Ltd
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Mylan
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global diuretic drugs market in 2022?

It was valued at US$ 98.8 Mn in 2022

How big will it be in 2031?

It is projected to reach more than US$ 157.2 Mn by 2031

What will be the CAGR during the forecast period (2023–2031)?

The CAGR is anticipated to be 5.5% from 2023 to 2031

What are the prominent trends that affect industry growth?

Surge in prevalence of chronic diseases and rise in awareness about benefits of diuretic drugs

Which region is likely to account for major share during the forecast period?

North America is expected to account for major share during the forecast period

Who are the prominent players in the business?

AstraZeneca, Aurobindo Pharma, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GSK plc, Hikma Pharmaceuticals PLC, Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Diuretic Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Diuretic Drugs Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Mergers & Acquisitions

        5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

        5.3. Regulatory Scenario by Region/globally

        5.4. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.5. Pipeline Analysis

    6. Global Diuretic Drugs Market Analysis and Forecast, By Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Drug Class, 2017-2031

            6.3.1. Carbonic Anhydrase Inhibitors

            6.3.2. Loop Diuretics

            6.3.3. Miscellaneous Diuretics

            6.3.4. Potassium-sparing Diuretics

            6.3.5. Thiazide Diuretics

        6.4. Market Attractiveness By Drug Class

    7. Global Diuretic Drugs Market Analysis and Forecast, By Route of Administration

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Route of Administration, 2017-2031

            7.3.1. Oral

            7.3.2. Parenteral

        7.4. Market Attractiveness By Route of Administration

    8. Global Diuretic Drugs Market Analysis and Forecast, By Indication

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Indication, 2017-2031

            8.3.1. Hypertension

            8.3.2. Heart Failure

            8.3.3. Kidney Stone

            8.3.4. Edema

            8.3.5. Others

        8.4. Market Attractiveness By Indication

    9. Global Diuretic Drugs Market Analysis and Forecast, By Distribution Channel

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast By Distribution Channel, 2017-2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Attractiveness By Distribution Channel

    10. Global Diuretic Drugs Market Analysis and Forecast, By Region

        10.1. Key Findings

        10.2. Market Value Forecast By Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Region

    11. North America Diuretic Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Drug Class, 2017-2031

            11.2.1. Carbonic Anhydrase Inhibitors

            11.2.2. Loop Diuretics

            11.2.3. Miscellaneous Diuretics

            11.2.4. Potassium-sparing Diuretics

            11.2.5. Thiazide Diuretics

        11.3. Market Value Forecast By Route of Administration, 2017-2031

            11.3.1. Oral

            11.3.2. Parenteral

        11.4. Market Value Forecast By Indication, 2017-2031

            11.4.1. Hypertension

            11.4.2. Heart Failure

            11.4.3. Kidney Stone

            11.4.4. Edema

            11.4.5. Others

        11.5. Market Value Forecast By Distribution Channel, 2017-2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Value Forecast By Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Drug Class

            11.7.2. By Route of Administration

            11.7.3. By Indication

            11.7.4. By Distribution Channel

            11.7.5. By Country

    12. Europe Diuretic Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Drug Class, 2017-2031

            12.2.1. Carbonic Anhydrase Inhibitors

            12.2.2. Loop Diuretics

            12.2.3. Miscellaneous Diuretics

            12.2.4. Potassium-sparing Diuretics

            12.2.5. Thiazide Diuretics

        12.3. Market Value Forecast By Route of Administration, 2017-2031

            12.3.1. Oral

            12.3.2. Parenteral

        12.4. Market Value Forecast By Indication, 2017-2031

            12.4.1. Hypertension

            12.4.2. Heart Failure

            12.4.3. Kidney Stone

            12.4.4. Edema

            12.4.5. Others

        12.5. Market Value Forecast By Distribution Channel, 2017-2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Value Forecast By Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Italy

            12.6.5. Spain

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Drug Class

            12.7.2. By Route of Administration

            12.7.3. By Indication

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region

    13. Asia Pacific Diuretic Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Drug Class, 2017-2031

            13.2.1. Carbonic Anhydrase Inhibitors

            13.2.2. Loop Diuretics

            13.2.3. Miscellaneous Diuretics

            13.2.4. Potassium-sparing Diuretics

            13.2.5. Thiazide Diuretics

        13.3. Market Value Forecast By Route of Administration, 2017-2031

            13.3.1. Oral

            13.3.2. Parenteral

        13.4. Market Value Forecast By Indication, 2017-2031

            13.4.1. Hypertension

            13.4.2. Heart Failure

            13.4.3. Kidney Stone

            13.4.4. Edema

            13.4.5. Others

        13.5. Market Value Forecast By Distribution Channel, 2017-2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Market Value Forecast By Country/Sub-region, 2017-2031

            13.6.1. Japan

            13.6.2. China

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Drug Class

            13.7.2. By Route of Administration

            13.7.3. By Indication

            13.7.4. By Distribution Channel

            13.7.5. By Country/Sub-region

    14. Latin America  Diuretic Drugs Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Drug Class, 2017-2031

            14.2.1. Carbonic Anhydrase Inhibitors

            14.2.2. Loop Diuretics

            14.2.3. Miscellaneous Diuretics

            14.2.4. Potassium-sparing Diuretics

            14.2.5. Thiazide Diuretics

        14.3. Market Value Forecast By Route of Administration, 2017-2031

            14.3.1. Oral

            14.3.2. Parenteral

        14.4. Market Value Forecast By Indication, 2017-2031

            14.4.1. Hypertension

            14.4.2. Heart Failure

            14.4.3. Kidney Stone

            14.4.4. Edema

            14.4.5. Others

        14.5. Market Value Forecast By Distribution Channel, 2017-2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Market Value Forecast By Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Drug Class

            14.7.2. By Route of Administration

            14.7.3. By Indication

            14.7.4. By Distribution Channel

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Diuretic Drugs Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast By Drug Class, 2017-2031

            15.2.1. Carbonic Anhydrase Inhibitors

            15.2.2. Loop Diuretics

            15.2.3. Miscellaneous Diuretics

            15.2.4. Potassium-sparing Diuretics

            15.2.5. Thiazide Diuretics

        15.3. Market Value Forecast By Route of Administration, 2017-2031

            15.3.1. Oral

            15.3.2. Parenteral

        15.4. Market Value Forecast By Indication, 2017-2031

            15.4.1. Hypertension

            15.4.2. Heart Failure

            15.4.3. Kidney Stone

            15.4.4. Edema

            15.4.5. Others

        15.5. Market Value Forecast By Distribution Channel, 2017-2031

            15.5.1. Hospital Pharmacies

            15.5.2. Retail Pharmacies

            15.5.3. Online Pharmacies

        15.6. Market Value Forecast By Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Drug Class

            15.7.2. By Route of Administration

            15.7.3. By Indication

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of companies)

        16.2. Market Share/Ranking Analysis By Company (2022)

        16.3. Company Profiles

            16.3.1. AstraZeneca

                16.3.1.1. Company Overview

                16.3.1.2. Drug Class Portfolio

                16.3.1.3. SWOT Analysis

                16.3.1.4. Strategic Overview

            16.3.2. Aurobindo Pharma

                16.3.2.1. Company Overview

                16.3.2.2. Drug Class Portfolio

                16.3.2.3. SWOT Analysis

                16.3.2.4. Strategic Overview

            16.3.3. Bayer AG

                16.3.3.1. Company Overview

                16.3.3.2. Drug Class Portfolio

                16.3.3.3. SWOT Analysis

                16.3.3.4. Strategic Overview

            16.3.4. Bristol-Myers Squibb Company

                16.3.4.1. Company Overview

                16.3.4.2. Drug Class Portfolio

                16.3.4.3. SWOT Analysis

                16.3.4.4. Strategic Overview

            16.3.5. Cipla Ltd

                16.3.5.1. Company Overview

                16.3.5.2. Drug Class Portfolio

                16.3.5.3. SWOT Analysis

                16.3.5.4. Strategic Overview

            16.3.6. F. Hoffmann-La Roche Ltd

                16.3.6.1. Company Overview

                16.3.6.2. Drug Class Portfolio

                16.3.6.3. SWOT Analysis

                16.3.6.4. Strategic Overview

            16.3.7. Fresenius Kabi AG

                16.3.7.1. Company Overview

                16.3.7.2. Drug Class Portfolio

                16.3.7.3. SWOT Analysis

                16.3.7.4. Strategic Overview

            16.3.8. GSK plc

                16.3.8.1. Company Overview

                16.3.8.2. Drug Class Portfolio

                16.3.8.3. SWOT Analysis

                16.3.8.4. Strategic Overview

            16.3.9. Hikma Pharmaceuticals PLC

                16.3.9.1. Company Overview

                16.3.9.2. Drug Class Portfolio

                16.3.9.3. SWOT Analysis

                16.3.9.4. Strategic Overview

            16.3.10. Mylan

                16.3.10.1. Company Overview

                16.3.10.2. Drug Class Portfolio

                16.3.10.3. SWOT Analysis

                16.3.10.4. Strategic Overview

            16.3.11. Novartis Pharmaceuticals Corporation

                16.3.11.1. Company Overview

                16.3.11.2. Drug Class Portfolio

                16.3.11.3. SWOT Analysis

                16.3.11.4. Strategic Overview

            16.3.12. Pfizer

                16.3.12.1. Company Overview

                16.3.12.2. Drug Class Portfolio

                16.3.12.3. SWOT Analysis

                16.3.12.4. Strategic Overview

            16.3.13. Sanofi

                16.3.13.1. Company Overview

                16.3.13.2. Drug Class Portfolio

                16.3.13.3. SWOT Analysis

                16.3.13.4. Strategic Overview

            16.3.14. Teva Pharmaceutical Industries Ltd

                16.3.14.1. Company Overview

                16.3.14.2. Drug Class Portfolio

                16.3.14.3. SWOT Analysis

                16.3.14.4. Strategic Overview

    List of Tables

    Table 01: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 02: Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 03: Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 04: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 05: Global Diuretic Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 08: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 09: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 10: North America Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 11: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 12: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 13: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 14: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 15: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 18: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 19: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 20: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 23: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 24: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 25: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 26: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 27: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

    Table 28: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031

    Table 29: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031

    Table 30: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Diuretic Drugs Market Value Share, by Drug Class, 2022

    Figure 03: Global Diuretic Drugs Market Value Share, by Route of Administration, 2022

    Figure 04: Global Diuretic Drugs Market Value Share, by Indication, 2022

    Figure 05: Global Diuretic Drugs Market Value Share, by Distribution Channel, 2022

    Figure 06 Global Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 07: Global Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 08: Global Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 09: Global Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 10: Global Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 11: Global Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 12: Global Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 13: Global Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 14: Global Diuretic Drugs Market Value Share Analysis, by Region, 2022 and 2031

    Figure 15: Global Diuretic Drugs Market Attractiveness Analysis, by Region, 2023-2031

    Figure 16: North America Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 17: North America Diuretic Drugs Market Value Share Analysis, by Country, 2022 and 2031

    Figure 18: North America Diuretic Drugs Market Attractiveness Analysis, by Country, 2023-2031

    Figure 19: North America Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 20: North America Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 21: North America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 22: North America Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 23: North America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 24: North America Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 25: North America Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 26: North America Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 27: Europe Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 28: Europe Diuretic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 29: Europe Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 30: Europe Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 31: Europe Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 32: Europe Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 33: Europe Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 34: Europe Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 35: Europe Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 36: Europe Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 37: Europe Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 38: Asia Pacific Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 39: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 40: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 41: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 42: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 43: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 44: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 45: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 46: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 47: Asia Pacific Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 48: Asia Pacific Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 49: Latin America Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 50: Latin America Diuretic Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

    Figure 51: Latin America Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

    Figure 52: Latin America Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 53: Latin America Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 54: Latin America Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 55: Latin America Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 56: Latin America Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 57: Latin America Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 58: Latin America Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 59: Latin America Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 60: Middle East & Africa Diuretic Drugs Market Value (US$ Mn) Forecast, 2017–2031

    Figure 61: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031

    Figure 62: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031

    Figure 63: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 64: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 65: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 66: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 67: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Indication, 2022 and 2031

    Figure 68: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Indication, 2023-2031

    Figure 69: Middle East & Africa Diuretic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 70: Middle East & Africa Diuretic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 71: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved